Evidence map›Paper›PMID 34545368›Full record

ArticlebioRxiv : the preprint server for biology2021

Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.

Gerald Wirnsberger, Vanessa Monteil, Brett Eaton, Elena Postnikova, Michael Murphy, Benedict Braunsfeld, Ian Crozier, Franz Kricek, Janine Niederhöfer, Alice Schwarzböck and 13 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 16 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 5 countries.

Gerald WirnsbergerApeiron Biologics, Vienna, Austria.
Vanessa MonteilKarolinska Institutet and Karolinska University Hospital, Unit of Clinical Microbiology, SE-17182, Stockholm, Sweden.
Brett EatonNIAID Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA.
Elena PostnikovaNIAID Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA.
Michael MurphyNIAID Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA.
Benedict BraunsfeldInstitute for Molecular Modeling and Simulation, University of Natural Resources and Life Sciences (BOKU), Austria.
Ian CrozierNIAID Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA.
Franz KricekNBS-C BioScience & Consulting GmbH, Vienna, Austria.
Janine NiederhöferApeiron Biologics, Vienna, Austria.
Alice SchwarzböckApeiron Biologics, Vienna, Austria.
Helene BreidApeiron Biologics, Vienna, Austria.
Anna Sanchez JimenezApeiron Biologics, Vienna, Austria.
Agnes Bugajska-SchretterApeiron Biologics, Vienna, Austria.
Alexander DohnalApeiron Biologics, Vienna, Austria.
Christine RufNBS-C BioScience & Consulting GmbH, Vienna, Austria.
Romana GugenbergerApeiron Biologics, Vienna, Austria.
Astrid HagelkruysInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria.
Nuria MontserratPluripotency for Organ Regeneration, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Michael R HolbrookNIAID Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA.
Chris OostenbrinkInstitute for Molecular Modeling and Simulation, University of Natural Resources and Life Sciences (BOKU), Austria.
Robert H ShoemakerChemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Ali MirazimiKarolinska Institutet and Karolinska University Hospital, Unit of Clinical Microbiology, SE-17182, Stockholm, Sweden.
Josef M PenningerInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria.
Apeiron Biologics (Austria) · ATBOKU University · ATInstitute of Molecular Biotechnology · ATKarolinska University Hospital · SEInstitució Catalana de Recerca i Estudis Avançats · ESNational Institutes of Health · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Austrian Science Fund FWF Z 271NCI NIH HHS 75N91019D00024
6 · The paper itself

Abstract

The recent emergence of multiple SARS-CoV-2 variants has caused considerable concern due to reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is therefore paramount to develop therapeutic strategies that inhibit all known and future SARS-CoV-2 variants. Here we report that all SARS-CoV-2 variants analyzed, including variants of concern (VOC) Alpha, Beta, Gamma, and Delta, exhibit enhanced binding affinity to clinical grade and phase 2 tested recombinant human soluble ACE2 (APN01). Importantly, soluble ACE2 neutralized infection of VeroE6 cells and human lung epithelial cells by multiple VOC strains with markedly enhanced potency when compared to reference SARS-CoV-2 isolates. Effective inhibition of infections with SARS-CoV-2 variants was validated and confirmed in two independent laboratories. These data show that SARS-CoV-2 variants that have emerged around the world, including current VOC and several variants of interest, can be inhibited by soluble ACE2, providing proof of principle of a pan-SARS-CoV-2 therapeutic.

Identifiers

PMID34545368
PMCPMC8452097
OpenAlexW3201051030

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.